In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Intellia Therapeutics Inc (NASDAQ: NTLA) closed at $7.16 up 4.22% from its previous closing price of $6.87. In other words, the price has increased by $4.22 from its previous closing price. On the day, 7.96 million shares were traded.
Ratios:
For a deeper understanding of Intellia Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.10.
On March 05, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
JP Morgan Downgraded its Overweight to Neutral on February 28, 2025, whereas the target price for the stock was revised from $45 to $13.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 29 ’25 when Bhanji Muna sold 265 shares for $8.50 per share. The transaction valued at 2,252 led to the insider holds 19,203 shares of the business.
Clark Eliana sold 679 shares of NTLA for $6,104 on Mar 04 ’25. The EVP, Chief Technical Officer now owns 95,369 shares after completing the transaction at $8.99 per share. On Mar 04 ’25, another insider, BASTA JAMES, who serves as the EVP, General Counsel of the company, sold 2,572 shares for $8.99 each. As a result, the insider received 23,122 and left with 111,925 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 16.28 while its Price-to-Book (P/B) ratio in mrq is 0.95.
Stock Price History:
Over the past 52 weeks, NTLA has reached a high of $28.18, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is -10.72%, while the 200-Day Moving Average is calculated to be -46.34%.
Shares Statistics:
A total of 103.54M shares are outstanding, with a floating share count of 97.48M. Insiders hold about 5.90% of the company’s shares, while institutions hold 91.97% stake in the company.
Earnings Estimates
The stock of Intellia Therapeutics Inc (NTLA) is currently drawing attention from 22.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$1.0, with high estimates of -$0.54 and low estimates of -$1.34.
Analysts are recommending an EPS of between -$2.38 and -$5.55 for the fiscal current year, implying an average EPS of -$4.24. EPS for the following year is -$3.95, with 26.0 analysts recommending between -$1.1 and -$6.1.
Revenue Estimates
A total of 27 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $210M, while the lowest revenue estimate was $16.63M, resulting in an average revenue estimate of $56.3M. In the same quarter a year ago, actual revenue was $57.88M
